Question-and-Answer Session
Operator
Thank you, sir. We will now begin the question-and-answer session. (Operator instructions) Our first question comes from the line of John Newman with Oppenheimer. Please go ahead.
John Newman – Oppenheimer
Hi, guys. Thanks for taking the question. First one, could you talk a little bit about your plans for stock buyback in 2009 and then I just have one follow-up.
Don Bailey
Sure, John. As we have been saying for the better part of the year, our plan is to split our free cash flow and use about half of it to buy back stock and half of it we are going to keep for opportunistic reasons. We don't need any cash to fund our current growth plan, but one never knows what is out there.
John Newman – Oppenheimer
Great.
Don Bailey
I'm going to check that – continue going forward.
John Newman – Oppenheimer
Great. Thank you. And then as a follow-up, hypothetically speaking, if a (inaudible) approved say sometime this year, could you talk a little bit about your potential marketing approach, assuming that you do get approval in IS, but that it may not come until say, the fourth quarter.
Steve Cartt
Well, John, this is Steve. I will try to spare Don's voice a little bit here and answer this one. Yes, so we are in full swing as far as planning for launch of our new IS indication and obviously we can't engage in any promotional efforts until the FDA gives their blessing on the indication, which we hope will be sometime this year. But obviously, it's fully in their accord at this point. We don't really know the timing on when a approval might take place, it could be later this year, it could be further off in the distance, we just don't know; and we are really planning for our launch, our view is that Acthar is the most effective drug and this is backed up by AAN and CNS guidelines, we have been published out there for quite a while. And nothing has changed in that regard so we are really – we believe we are operating from a position of strength and we have the best drug and the most favorable data and we are really approaching the market from that standpoint. But in the meantime, we are getting ready for a launch and hopefully it will take place later this year.
- To read the full transcript on Seeking Alpha, click here »
